FSRH Clinical Effectiveness Unit comment on the use of Sodium Valproate and its pregnancy risks - 2016
Posted 8 February 2016
Date: 08 Feb 2016
Type: FSRH Clinical Guidance and Clinical Statements
FSRH’s Clinical Effectiveness Unit comments on Sodium Valproate and the risks it carries if used during pregnancy.
This statement follows the Medical and Healthcare products Regulatory Agency (MHRA) launch of a toolkit for healthcare professionals to highlight Sodium Valproate’s teratogenic effects.
Related Links
Valproate Information
This information is for you if you are a girl or a woman taking any medicine containing valproate. It contains key information about the risks of valproate in pregnancy.